Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLC

Summary The therapeutic landscape of epidermal growth factor receptor (EGFR)-mutation-positive non-small cell lung cancer (NSCLC) is continually evolving. A recent manuscript in Nature by Robichaux and colleagues 1 reports on a structure-based classification of EGFR mutations to help predict sensitivities to EGFR inhibitors in NSCLC that may ultimately improve patient outcomes.